Corporate Update: NuCana PLC (NCNA)
Trading Overview
NuCana PLC’s shares (ticker NCNA) closed down 4.37 % during the 24‑hour period ending 11:26 AM Central European Time on Thursday, 22 October 2026. The current trading price sits at approximately USD 0.96, with an outstanding supply of 4.3 million shares. The company’s market capitalisation is USD 4.3 million, and trading volume over the last day was roughly USD 29 000. From the end of last month to the present, NuCana’s share price has fallen 27.67 %.
The 200‑day simple moving average is USD 1.84, and the 52‑week range spans a high of USD 4.55 (recorded on 10 December 2025) to a low of USD 0.95 (on 2 October 2026).
Peer Performance (Last 24 Hours)
| Symbol | 24‑h % Change | Current Price | Market Cap | P/E (if available) |
|---|---|---|---|---|
| RNK.L | +5.1 % | GBX 78 | GBX 503.8 m | 12.87 |
| MLSEQ.PA | 0 % | EUR 0 | EUR 4.3 m | — |
| GBG.L | –1.27 % | GBX 155.62 | GBX 472.2 m | — |
| STEM.L | +4.19 % | GBX 295.11 | GBX 501 m | 30.54 |
| CRW.L | +1.27 % | GBX 1,115 | GBX 510.1 m | 28.60 |
Strategic Context
NuCana PLC is headquartered in Edinburgh and operates as a biotechnology firm focused on the development of anti‑cancer therapeutics across a broad spectrum of malignancies, including ovarian, biliary, pancreatic, colorectal, haematological, and breast cancers. Its pipeline leverages a proprietary technology platform that enables the production of oncology medicines tailored to the needs of patients in the United Kingdom and the United States. The company has been publicly listed on the Nasdaq since its IPO on 28 September 2017.
Forward‑Looking Perspective
Despite recent volatility, the company’s continued investment in late‑stage clinical development and its strategic partnerships with key oncology centers position it to capitalize on unmet medical needs. Analysts note that while the current share price reflects short‑term market sentiment, NuCana’s underlying assets—particularly its pipeline candidates—may provide significant upside as regulatory milestones are met. Investors monitoring the biotech sector should consider the company’s recent performance relative to its peers, noting that several comparables have posted gains in the same period, signalling sector resilience.
For further details, including the latest clinical data and financial disclosures, visit NuCana’s website at www.nucana.com .
